Catalent has entered a collaboration with Ennaid Therapeutics to develop an oral, antiviral treatment targeting COVID-19. Catalent will develop a powder-in-capsule formulation of Ennaid’s ENU200 program, a repurposed oral antiviral drug.
 
ENU200 was selected by Ennaid as a candidate to treat COVID-19 following a bioinformatic search for in silico identification of prior-approved chemical compounds blocking the coronavirus proteins, spike-S glycoprotein and the key coronavirus enzyme, Mpro. Catalent’s development site at San Diego will manufacture roller-compacted formulations of ENU200 in capsules for further investigation.
 
“During this pandemic we have seen that numerous companies are looking to repurpose existing antiviral drugs to target COVID-19, and we are supporting our development partners in reacting quickly and effectively to manufacture material for clinical trials,” commented Jonathan Arnold, President, Oral and Specialty Delivery at Catalent. “Our experience with similar formulation and manufacturing processes and overcoming scale up challenges with roller compaction has meant that we are able to rapidly deliver Ennaid’s demand for drug product in a matter of weeks.”
 
Catalent’s San Diego facility is one of three global centers of excellence in early-phase development focusing on preclinical to clinical Phase IIb formulation, analytical, and manufacturing solutions for orally delivered small molecules.